Xofluza and Tamiflu reduce flu symptoms by roughly the same amount of time, about 54 hours compared to 80 hours with no treatment. Where they differ meaningfully is convenience, how fast they stop you from spreading the virus, and cost. Neither drug is categorically better; the right choice depends on what matters most to you.
How They Compare on Symptom Relief
In the phase three clinical trial (CAPSTONE-1), patients with confirmed influenza who took Xofluza recovered in a median of 53.7 hours. Those who took Tamiflu recovered in 53.8 hours. That’s essentially identical, and both cut about a full day off the illness compared to placebo. So if your only concern is “how fast will I feel better,” neither drug has an edge.
Both medications need to be started within 48 hours of your first symptoms to work. The sooner you begin treatment, the more benefit you get. Patients who started within 24 hours of symptom onset saw the most improvement in both groups.
The Biggest Practical Difference: One Dose vs. Ten
Xofluza is a single dose. You take one pill and you’re done. Tamiflu requires two pills a day for five days, totaling ten doses over a full course. For most people, this is the most noticeable difference between the two drugs.
A single dose is easier to complete, which matters when you’re sick. Missing doses of Tamiflu reduces its effectiveness, and a five-day regimen is easy to abandon once you start feeling better. Xofluza removes that problem entirely. If you’re treating a child or someone who has trouble keeping up with medication schedules, the one-dose approach is a genuine advantage.
Xofluza Clears the Virus Much Faster
While both drugs relieve symptoms on a similar timeline, Xofluza is significantly better at stopping viral shedding, the period when your body is actively releasing flu virus and you can infect others. In studies, patients on Xofluza stopped shedding virus in a median of about 24 hours compared to roughly 76 hours for those on Tamiflu. That’s more than two days faster.
This matters most in households, workplaces, or care facilities where you’re trying to protect the people around you. Xofluza is also FDA-approved for post-exposure prevention: if someone in your household has the flu, a single dose of Xofluza can help keep you from getting sick. For families with elderly or immunocompromised members, the faster viral clearance could be a deciding factor.
Side Effects
Both drugs are generally well tolerated. Tamiflu’s most common side effects are nausea and vomiting, which can be significant enough that some people stop taking it early. Taking Tamiflu with food reduces stomach upset. Tamiflu also carries a well-known (though rare) association with neuropsychiatric effects, including abnormal behavior, hallucinations, and delirium. These reports are most common in children and adolescents and led to safety warnings in several countries, though a direct causal link remains debated.
Xofluza tends to cause fewer gastrointestinal problems. Its side effect profile in trials was similar to placebo, with no strong signal for the neuropsychiatric events associated with Tamiflu. Post-market safety monitoring has flagged vomiting as a reported event, but overall, Xofluza appears to be the gentler option on the stomach.
Resistance Is Xofluza’s Weak Spot
One notable concern with Xofluza is drug resistance. Roughly 10% of patients treated with Xofluza develop flu virus variants that are resistant to the drug during treatment. This happens because Xofluza targets a single viral enzyme, and the flu virus can mutate at that site relatively quickly. When resistance develops, the drug becomes less effective, and symptom improvement can slow or stall.
Resistance rates are even higher in children under five, which is why the FDA does not approve Xofluza for that age group. Tamiflu has a much lower rate of treatment-emergent resistance in most patient populations and remains the standard choice for very young children (it’s approved down to two weeks of age for treatment).
Age and Eligibility
Tamiflu covers a broader age range. It’s approved for treating flu in patients as young as two weeks old, making it the go-to antiviral for infants and toddlers. Xofluza is approved for ages five and up, both for treatment and for post-exposure prevention. For children under five, Tamiflu is your only oral antiviral option.
Both drugs are approved for patients at high risk of flu complications, including people with asthma, diabetes, heart disease, and those who are immunocompromised. Xofluza was specifically studied in high-risk populations in the CAPSTONE-2 trial and showed comparable benefits to Tamiflu in preventing complications like bronchitis and pneumonia.
Cost Without Insurance
At retail price without insurance, the two drugs land in a similar range but get there differently. A full course of brand-name Tamiflu (ten capsules) runs about $156. A single Xofluza tablet costs roughly $173. However, generic oseltamivir (the active ingredient in Tamiflu) is widely available and often significantly cheaper, sometimes under $30 with a coupon. Xofluza does not yet have a generic version, so its price stays near that $173 mark unless your insurance covers it or you use a manufacturer discount program.
If cost is a major factor and you don’t mind the five-day regimen, generic oseltamivir is the most affordable option by a wide margin.
Which One Should You Choose
If you want the simplest possible treatment and you’re five or older, Xofluza’s single dose and faster viral clearance make it appealing, especially if you’re trying to protect vulnerable people around you. If you’re treating a young child, need the cheapest option, or are concerned about drug resistance, Tamiflu (or its generic) is the more practical choice. Both drugs shorten your illness by about the same amount, so you won’t feel better faster with one over the other. The real differences are in convenience, cost, contagiousness, and who’s eligible.